Kamada Ltd. announced that the U.S. Food and Drug Administration has approved its new plasma collection center in San Antonio, Texas, allowing the facility to begin commercial sales of normal source plasma. The 11,100‑square‑foot center can accommodate up to 50 donor beds and is projected to collect roughly 50,000 liters of plasma per year once fully operational.
"We are extremely pleased to announce the FDA approval of our state‑of‑the‑art plasma collection center in San Antonio, and for the work of our dedicated team of plasma collection experts who achieved the approval of this facility," said Kamada CEO Amir London. London added, "Our three Texas‑based sites, in Houston, San Antonio and Beaumont, provide us with significant capacity of specialty and normal source plasma collection."
The new center will generate an estimated $8 million to $10 million in annual revenue from normal source plasma sales when it reaches full capacity. This figure represents a new revenue stream that complements Kamada’s existing portfolio of specialty plasma‑derived products.
Kamada’s expansion into a third Texas site is a key element of its vertical‑integration strategy, which seeks to secure 20‑25 % of its specialty plasma needs internally. By owning more of the supply chain, the company can reduce cost of goods and improve margins on its high‑margin specialty products while also creating a stable source of normal source plasma for future product development.
In the context of recent financial results, Kamada reported a Q4 2025 earnings miss, with earnings per share of $0.06 versus analyst expectations of $0.09–$0.10 and revenue of $44.68 million versus $45.42 million. Despite the miss, management reaffirmed its 2026 guidance, projecting revenue of $200 million to $205 million and adjusted EBITDA of $50 million to $53 million. The company’s full‑year 2025 revenue of $180.5 million and adjusted EBITDA of $42 million underscore the growth trajectory that the new center is expected to support.
The FDA approval of the San Antonio facility strengthens Kamada’s operational resilience and positions the company to capture additional market share in the plasma collection sector while reinforcing its long‑term financial outlook.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.